INM insider filings

InMed Pharmaceuticals Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-27. Screen INM transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 6 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
ADAR1 Capital Management, LLC — 10% owner & Schneeberger Daniel — 10% owner615 legs · 155,584 sh · $203,800——

Recent insider filings — InMed Pharmaceuticals Inc.

FiledFormInsiderReported transactionsSource
2026-10-274ADAR1 Capital Management, LLC — 10% owner
Schneeberger Daniel — 10% owner
Purchase (P): 4 @ $1.32EDGAR
2026-10-204ADAR1 Capital Management, LLC — 10% owner
Schneeberger Daniel — 10% owner
Purchase (P): 1 @ $1.32 · Purchase (P): 1,086 @ $1.32EDGAR
2026-10-154ADAR1 Capital Management, LLC — 10% owner
Schneeberger Daniel — 10% owner
Purchase (P): 564 @ $1.33 · Purchase (P): 8,021 @ $1.33 · Purchase (P): 984 @ $1.32EDGAR
2026-10-084ADAR1 Capital Management, LLC — 10% owner
Schneeberger Daniel — 10% owner
Purchase (P): 5,601 @ $1.33 · Purchase (P): 3,046 @ $1.33 · Purchase (P): 2,256 @ $1.33EDGAR
2026-10-054ADAR1 Capital Management, LLC — 10% owner
Schneeberger Daniel — 10% owner
Purchase (P): 16,431 @ $1.33 · Purchase (P): 8,307 @ $1.33 · Purchase (P): 18,182 @ $1.33EDGAR
2026-09-164ADAR1 Capital Management, LLC — 10% owner
Schneeberger Daniel — 10% owner
Purchase (P): 28,505 @ $1.29 · Purchase (P): 54,256 @ $1.30 · Purchase (P): 8,340 @ $1.29EDGAR
2026-07-174ADAR1 Capital Management, LLC — 10% owner
Schneeberger Daniel — 10% owner
Purchase (P): 1,000 @ $1.55EDGAR
2026-07-164Vivo Opportunity, LLC — 10% owner
Vivo Opportunity Fund Holdings, L.P. — 10% owner
Vivo Opportunity Cayman, LLC — 10% owner
Vivo Opportunity Cayman Fund, L.P. — 10% owner
Purchase (P): 4,882 @ $1.55 · Purchase (P): 493 @ $1.55 · Purchase (P): 13,761 @ $1.55 · Purchase (P): 1,389 @ $1.55 · Purchase (P): 19 @ $1.55 · Purchase (P): 2 @ $1.55EDGAR
2026-07-024Vivo Opportunity, LLC — 10% owner
Vivo Opportunity Fund Holdings, L.P. — 10% owner
Vivo Opportunity Cayman, LLC — 10% owner
Vivo Opportunity Cayman Fund, L.P. — 10% owner
Purchase (P): 545 @ $1.54 · Purchase (P): 55 @ $1.54 · Purchase (P): 3,946 @ $1.55 · Purchase (P): 398 @ $1.55 · Purchase (P): 1,460 @ $1.55 · Purchase (P): 147 @ $1.55EDGAR
2026-06-104Vivo Opportunity, LLC — 10% owner
Vivo Opportunity Fund Holdings, L.P. — 10% owner
Vivo Opportunity Cayman, LLC — 10% owner
Vivo Opportunity Cayman Fund, L.P. — 10% owner
Purchase (P): 51,056 @ $1.56 · Purchase (P): 5,154 @ $1.56 · Purchase (P): 30,882 @ $1.69 · Purchase (P): 3,118 @ $1.69 · Purchase (P): 16,164 @ $1.57 · Purchase (P): 1,632 @ $1.57 · +12 moreEDGAR
2026-05-214ADAR1 Capital Management, LLC — 10% owner
Schneeberger Daniel — 10% owner
Purchase (P): 68,551 @ $1.60 · Purchase (P): 200,000 @ $1.56 · Purchase (P): 200,000 @ $1.50EDGAR
2025-12-194Johnson Shane Aaron — Sr VP & General ManagerGrant/award (A): 8,500 (derivative) @ $0EDGAR
2025-12-194Lemerond Nicole — DirectorGrant/award (A): 1,750 (derivative) @ $0EDGAR
2025-12-194Klompas Neil A — DirectorGrant/award (A): 1,750 (derivative) @ $0EDGAR
2025-12-194Jagpal Netta — Chief Financial OfficerGrant/award (A): 18,000 (derivative) @ $0EDGAR
2025-12-194WOUDENBERG MICHAEL — Chief Operating OfficerGrant/award (A): 18,000 (derivative) @ $0EDGAR
2025-12-194Bathery John Steven — DirectorGrant/award (A): 1,750 (derivative) @ $0EDGAR
2025-12-194HSU ERIC C — Sr. VP, Pre-Clinical Res/DevGrant/award (A): 13,000 (derivative) @ $0EDGAR
2025-12-194ADAMS ERIC A — President & CEO, DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2025-12-194HULL ANDREW — DirectorGrant/award (A): 1,750 (derivative) @ $0EDGAR
2025-12-174HULL ANDREW — DirectorCode (H): 14 (derivative) @ $0EDGAR
2025-12-174ADAMS ERIC A — President & CEO, DirectorCode (H): 250 (derivative) @ $0EDGAR
2025-12-174WOUDENBERG MICHAEL — Chief Operating OfficerCode (H): 60 (derivative) @ $0EDGAR
2025-12-174HSU ERIC C — Sr. VP, Pre-Clinical Res/DevCode (H): 70 (derivative) @ $0EDGAR
2025-10-214Klompas Neil A — DirectorGrant/award (A): 3,500 (derivative) @ $0EDGAR
2025-02-034HULL ANDREW — DirectorCode (H): 2 (derivative) @ $0EDGAR
2024-12-234HSU ERIC C — Sr. VP, Pre-Clinical Res/DevGrant/award (A): 2,750 (derivative) @ $0EDGAR
2024-12-234Baldasare Bryan T — DirectorGrant/award (A): 550 (derivative) @ $0EDGAR
2024-12-234Johnson Shane Aaron — Sr VP & General ManagerGrant/award (A): 1,500 (derivative) @ $0EDGAR
2024-12-234Jagpal Netta — Chief Financial OfficerGrant/award (A): 3,750 (derivative) @ $0EDGAR
2024-12-234Lemerond Nicole — DirectorGrant/award (A): 550 (derivative) @ $0EDGAR
2024-12-234WOUDENBERG MICHAEL — Chief Operating OfficerGrant/award (A): 3,750 (derivative) @ $0EDGAR
2024-12-234ADAMS ERIC A — President & CEO, DirectorGrant/award (A): 6,250 (derivative) @ $0EDGAR
2024-12-234HULL ANDREW — DirectorGrant/award (A): 550 (derivative) @ $0EDGAR
2024-12-234Grove Janet P — DirectorGrant/award (A): 550 (derivative) @ $0EDGAR
2024-08-024MANCINI ALEXANDRA DIANE JANETSale (S): 240 @ $0.18EDGAR
2024-05-284WOUDENBERG MICHAEL — Chief Operating OfficerCode (H): 394 (derivative) @ $0EDGAR
2024-05-284HSU ERIC C — Sr. VP, Pre-Clinical Res/DevCode (H): 545 (derivative) @ $0EDGAR
2024-05-284ADAMS ERIC A — President & CEO, DirectorCode (H): 1,139 (derivative) @ $0EDGAR
2024-05-284MANCINI ALEXANDRA DIANE JANET — Sr VP, Clinical Reg AffairsCode (H): 485 (derivative) @ $0EDGAR
2024-03-054HULL ANDREW — DirectorCode (H): 42 (derivative) @ $0EDGAR
2024-03-054HSU ERIC C — Sr. VP, Pre-Clinical Res/DevCode (H): 309 (derivative) @ $0EDGAR
2024-03-054MANCINI ALEXANDRA DIANE JANET — Sr VP, Clinical Reg AffairsCode (H): 121 (derivative) @ $0EDGAR
2024-02-224HULL ANDREW — DirectorPurchase (P): 37,500 @ $0.39EDGAR
2024-02-214ADAMS ERIC A — President & CEO, DirectorPurchase (P): 41,600 @ $0.36EDGAR
2023-12-264ADAMS ERIC A — President & CEO, DirectorGrant/award (A): 136,000 (derivative) @ $0EDGAR
2023-12-264Baldasare Bryan T — DirectorGrant/award (A): 7,100 (derivative) @ $0EDGAR
2023-12-264MANCINI ALEXANDRA DIANE JANET — Sr VP, Clinical Reg AffairsGrant/award (A): 45,000 (derivative) @ $0EDGAR
2023-12-264HULL ANDREW — DirectorGrant/award (A): 7,100 (derivative) @ $0EDGAR
2023-12-264Grove Janet P — DirectorGrant/award (A): 7,100 (derivative) @ $0EDGAR

Recent 8-K events — InMed Pharmaceuticals Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-208-K4.01 — Changes in Registrant's Certifying Accountant
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-168-K2.01 — Completion of Acquisition or Disposition of Assets
2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-108-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
2.02 — Results of Operations and Financial Condition
3.02 — Unregistered Sales of Equity Securities
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
5.05 — Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
5.06 — Change in Shell Company Status
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-098-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-058-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
5.07 — Submission of Matters to a Vote of Security Holders
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-058-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-038-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-188-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-228-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-108-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=INM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs